GSK•benzinga•
The FDA Has Accepted For Review GSK's Regulatory Application Of A Prefilled Syringe Presentation Of Shingrix For The Prevention Of Shingles (Herpes Zoster), An FDA Decision Is Expected By 20 June 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga